αvβ3 integrin inhibitors

A compound of the formula I

• X—Y—Z—R1—CH2—R2(R4)—CH2—CO—R5
• in which
• X is H2N—C(═NH)—, H2N—C(═NH)—NH—, A—C(═NH)—NH—, Het1- or Het1-NH—,
• where the primary amino groups may also be provided with conventional amino-protecting groups,
• Y is
• in which one, two, three or four methylene groups may be replaced by N, O and/or S,
• Z is —O—, —NH—, —NA—, —CH(OH)—, —CH(OA)—, —CHA, —CA2—or —S—,
• R1 is phenylene which is unsubstitued or mono-, di- or trisubstituted by F, Cl, Br, A, OA, OCF3, or CN,
• R2 is N, CH, or CA,
• R3 is H, F, Cl, Br, A, OA or OCF3,
• R4 is phenyl, naphthyl or Het2, each of which is unsubstituted or mono- or polysubstituted by A, aryl, or CF3,
• R5 is OH, OA, NH2, NHA or NA2,
• Het1 is a mono- or bicylic heterocylic radical having from 1 to 4 N atoms, which may be unsubstituted or mono- or disubstituted by NH2,
• Het2 is an aromatic mono- or bicylic heterocylic radical having from 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by F, Cl, Br, A, OA, SA, OCF3, —CO—A, CN, COOA, CONH2, CONHA, CONA2, or NO2,
• aryl is phenyl which is unsubstituted or mono-, di-, or trisubstituted by Hal, A or OA,
• A is alkyl having 1-12 carbon atoms,
• n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12,
• m, o are each, independently of one another, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, or
• a physiologically acceptable salt or solvate thereof.